Charting Only, page-215

I can see your point. it doesnt matter how good your drug is if you cant afford to progress it.

The 4th cohort of the phase 1a is now having the largest dose hitting its arm (well inter cranial). The 1st patient dosed early March. Hopefully the drug can progress beyond stable disease. We sould Hopefully know by end of year.

CarT is an expensive treatment. Forfeiture share payments to onboard experts is also expensive (these end soon). So cash burn is high. But thre GBM pathway will be an accelerated one to approval if the drug is proven to work.

This market cap, for this pipeline, allows the potential for many multiples of growth, even with future dilution.

It is still a high risk investment. But high risk means potential for huge gains or loss.